Urethral Cancer Pipeline Review, H2 2012


#146175

39pages

Global Markets Direct

$ 2000

In Stock

 
Global Markets Directs, 'Urethral Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Urethral Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urethral Cancer. Urethral Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Urethral Cancer.
  • A review of the Urethral Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Urethral Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Urethral Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Urethral Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Urethral Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Urethral Cancer 7
Urethral Cancer Therapeutics under Development by Companies 9
Urethral Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Urethral Cancer Therapeutics Products under Development by Companies 14
Urethral Cancer Therapeutics Products under Investigation by Universities/Institutes 15
Companies Involved in Urethral Cancer Therapeutics Development 16
Eli Lilly and Company 16
Altor BioScience Corporation 17
Urethral Cancer Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
interferon alfa-2b - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
irinotecan hydrochloride - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Gemcitabine + Cisplatin + Bevacizumab - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
eribulin mesylate - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Carboplatin + Gemcitabine + Paclitaxel - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IMC-1121B + Docetaxel - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ALT-801 + Gemcitabine + Cisplatin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Urethral Cancer Therapeutics Discontinued Products 36
Urethral Cancer Therapeutics - Dormant Products 37

Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39
 
Number of Products Under Development for Urethral Cancer, H2 2012 7
Products under Development for Urethral Cancer Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Eli Lilly and Company, H2 2012 16
Altor BioScience Corporation, H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Urethral Cancer Therapeutics Discontinued Products 36
Urethral Cancer Therapeutics Dormant Products 37 
Number of Products under Development for Urethral Cancer, H2 2012 7
Products under Development for Urethral Cancer Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23